WO2014084460A1 - Composition comprising acanthopanax koreanum extract as active ingredient for preventing or treating neuropsychiatric disorders - Google Patents

Composition comprising acanthopanax koreanum extract as active ingredient for preventing or treating neuropsychiatric disorders Download PDF

Info

Publication number
WO2014084460A1
WO2014084460A1 PCT/KR2013/003257 KR2013003257W WO2014084460A1 WO 2014084460 A1 WO2014084460 A1 WO 2014084460A1 KR 2013003257 W KR2013003257 W KR 2013003257W WO 2014084460 A1 WO2014084460 A1 WO 2014084460A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
present
acanthopanax koreanum
active ingredient
Prior art date
Application number
PCT/KR2013/003257
Other languages
French (fr)
Korean (ko)
Inventor
홍은영
심재석
김상현
류종훈
정재훈
Original Assignee
씨제이제일제당 (주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨제이제일제당 (주) filed Critical 씨제이제일제당 (주)
Publication of WO2014084460A1 publication Critical patent/WO2014084460A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254Acanthopanax or Eleutherococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/37Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction

Definitions

  • the present invention relates to a composition comprising an extract of Acanthopanax koreanum as an active ingredient, specifically, a pharmaceutical composition for the prevention or treatment of neuropsychiatric diseases including the extract of S. a. Food composition for the prevention or improvement of the method of preparing the composition; It relates to a pharmaceutical composition and a food composition for neuronal regeneration comprising an extract of the island stem.
  • Acanthopanax koreanum Nakai is an Eleutherococcus species and belongs to the family Araliaceae. It is a special species of Jeju that grows at 1400m above sea level of Jeju Island in Korea. It is also called Tamraukogi. The flowering period of the island is in May, and the ripening season begins in September. The islands have strong thorns and have a habit of stalks hanging on the ground, and growth is very vigorous. The roots have a distinctive fragrance and are divided into main root, root and root (Han KJ et al., Growth of seeding and germination characteristics of Acanthopanax koreanum Nakai.Korean J. Medicinal Crop Sci. 11, 46-52, 2003, Byung-Sun Lim And 2 others, Growth Characteristics and Botanical Vegetation Survey of Ogalpi Jiri and Island Ogalpi, Journal of the Plant Resources Society of Korea, 12, 125-132, 1999).
  • the main components of the roots, stems and leaves of the isogapi include glycosides, flavonoids, diterpenoids, and the like, and in particular, it is known that the root contains acanthoic acid (Lim, JH et al, Changes in major constituents by soaking of Acanthopanax koreanum with spirit solution.J. Korean Soc.Appl. Biol. Chem., 48, 166-172, 2005).
  • the island ogapi is traditionally used as a therapeutic agent to lighten the body, mainly by using roots, and has been reported to be used for diseases such as obesity, rheumatism, diabetes and hepatitis (Yang, EJ et al. Acanthopanax koreanum fruit waste). inhibits lipopolysaccharide-induced production of nitric oxide and prostaglandin E2 in RAW 264.7 macrophages.J. Biomed Biotechnol., 2010, 715-739, 2010).
  • depression is a common disease, and in the United States, more than 18 million people suffer from depression every year, and the lifetime prevalence of depression in Korea is known to be about 15% of the population, but many patients in Korea are suffering from lack of awareness or social prejudice against mental illness. Hesitant to take antidepressants.
  • Anxiety disorder is a psychological disorder mainly manifested by anxiety emotions, and has a lot of negative effects on daily life due to tension emotions that continuously show various symptoms such as autonomic nervous system disorders, muscle stiffness, and motor disorders.
  • GABA GABA nervous system
  • serotonin nervous system noradrenaline nervous system and neuropeptide system. Due to its side effects, there are many restrictions.
  • the present inventors have made diligent efforts to find natural products having a neurological regeneration effect while preventing and treating various mental disorders such as depression and anxiety disorder. It was confirmed that the anti-anxiety activity, and completed the present invention.
  • One object of the present invention to provide a pharmaceutical composition for the prevention or treatment of neuropsychiatric disorders, including Acanthopanax koreanum extract as an active ingredient.
  • Still another object of the present invention is to provide a method of treating neuropsychiatric disorders, comprising administering the pharmaceutical composition to an individual suspected of neuropsychiatric disorders.
  • Still another object of the present invention is to provide a method for preparing the composition.
  • Still another object of the present invention is to provide a pharmaceutical composition for nerve regeneration, comprising an extract of Acanthopanax koreanum as an active ingredient.
  • Still another object of the present invention is to provide a neurological regeneration food composition
  • a neurological regeneration food composition comprising an extract of Acanthopanax koreanum as an active ingredient.
  • Seogagapi extract of the present invention is derived from a natural product that has been used as a natural medicine for a long time without the side effects, but also a therapeutic effect against neuropsychiatric diseases such as depression, anxiety disorders; And because it has a nerve regeneration effect, the composition of the present invention comprising isogapi extract is used for the prevention or treatment of neuropsychiatric diseases; And neural regeneration.
  • 1 is a flow chart illustrating a method for preparing sesame stem extract according to an embodiment of the present invention.
  • Figure 2 is a graph comparing the neuronal regeneration of the brain in the mice administered the extract of the island of the present invention compared with the control.
  • Figure 3 is a graph comparing the immobility time with the control group in the forced swimming test for the mice administered the isogapi extract of the present invention.
  • Figure 4 is a graph comparing the time spent in the open space in the raised cruciform with the control mice for the mice administered the isogapi extract of the present invention.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of neuropsychiatric diseases, including Acanthopanax koreanum extract as an active ingredient.
  • the term " Acanthopanax koreanum" refers to a tree belonging to the family Araliaceae as an Eleutherococcus species, and the island canopy can be used interchangeably with tamra orgapi.
  • Seogagapi is divided into leaves, stems, roots, and fruits, and the roots are divided into main roots, roots, and roots.
  • the isogapi is known to enhance liver disease, anti-inflammatory and immunity, but the efficacy on neuropsychiatric diseases is not known, it was newly identified by the present inventors.
  • the islands can be used in nature or purchased commercially available, but is not limited thereto.
  • acanthopanax koreanum extract refers to an extract obtained by extracting isopipi.
  • the island extract is preferably an extract obtained by extracting the root or / and stem of the island.
  • the sesame stem extract may be prepared by extracting the sesame stem pulverized product using water, an alcohol having 1 to 6 carbon atoms, preferably an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
  • Water after the extraction process may be prepared as an extract of the present invention through filtration, concentrated under reduced pressure and drying in sequence, without being particularly limited thereto, extracts, dilutions or concentrates of extracts, dried products obtained by drying the extracts, or All these modifiers or purified products are included.
  • the sesame stem extract can be extracted from various organs of natural, hybrid, varieties of plants. In one embodiment of the present invention was extracted using 70% ethanol from the roots and stems of the island stem (Example 1).
  • Seogagapi extract of the present invention is characterized in that it comprises at least one component selected from the group consisting of eleutheroside B (eleutheroside B), eleutheroside E (eleutheroside E) and achanthoic acid.
  • the term "eleutheroside B” refers to a phenyl propanoid glycoside, also named syringin, and has a structure represented by the following Chemical Formula 1.
  • the term "eleutheroside E” refers to a glucoside compound named Acanthoside D and has a structure represented by the following Chemical Formula 2.
  • the eleuteroside E is known to have hepatoprotective activity, detoxification effect and the like.
  • acanthoic acid is known to have potent analgesic components, such as potent analgesic suppression, anti-inflammatory activity, and maintenance of the homeostasis of the immune system.
  • the isogapi extract of the present invention comprising the above eleuteroside B, eleuteroside E and acantosan has neuronal regeneration, anti-anxiety and antidepressant activity, in the prevention or treatment of various neuropsychiatric diseases It can be usefully used.
  • neuropsychiatric disorder means a mental disorder that may be caused by the development of neurons, and the like.
  • the neuropsychiatric disorders include anxiety, depression or affective disorders that can be treated by the extract of sesame stem of the present invention.
  • the anxiety disorder refers to a mental illness that causes disorders in daily life due to abnormal and pathological anxiety and fear
  • the depression is a disorder in which motivation and depression are the main symptoms, causing various cognitive and mental and physical symptoms, thereby causing daily functions. Means a disease that brings down the.
  • the affective disorder refers to a type of neuropsychiatric disorder whose main symptom is moody or depressed mood.
  • prevention refers to any action that inhibits or delays the onset of neuropsychiatric disorders by the administration of the composition
  • treatment means that symptoms caused by neuropsychiatric disorders are improved by administration of the composition. It means any action that is beneficially changed.
  • the pharmaceutical composition comprising the sesame stem extract of the present invention may further comprise a suitable carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition.
  • a suitable carrier excipient or diluent commonly used in the preparation of the pharmaceutical composition.
  • the content of the extract or fractions thereof included in the composition is not particularly limited, but may be 0.0001% to 99.99% by weight, preferably 0.001% to 50% by weight based on the total weight of the composition.
  • the pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have one formulation and can be a variety of oral or parenteral formulations. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used.
  • Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • composition of the present invention may be administered in a pharmaceutically effective amount.
  • the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type and severity, age, sex, disease of the individual. It may be determined according to the type, activity of the drug, sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical field.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations.
  • the pharmaceutical composition of the present invention is preferably administered parenterally or orally in the range of 0.001 to 100 ⁇ g / kg, more preferably in the range of 0.01 to 100 ⁇ g / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the present invention in any aspect.
  • the composition may be administered to various mammals such as rats, livestock, humans, etc. by various routes, and the mode of administration may be any conventional method in the art. Without limitation, it may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections.
  • the sesame stem extract of the present invention was prepared from the root and stem of the sesame stem using 70% ethanol extract was confirmed that the sesame stem extract has a neuronal regeneration effect in the hippocampal region in the stress-induced brain (Fig. 2, Experimental Example 1).
  • the sesame stem extract of the present invention has antidepressant activity through the forced swimming method of the mouse, and thus the composition of the present invention can be usefully used for the treatment of depression, which is a kind of neuropsychiatric disease (FIG. 3, Experimental Example 2).
  • the sesame stem extract of the present invention increases the time to stay in the open space in the cross maze test, it is useful for the prevention and treatment of anxiety disorder (Fig. 4, Experimental Example 3).
  • the present invention provides a method of treating neuropsychiatric disorders comprising administering the composition to a subject suspected of neuropsychiatric disorders.
  • composition and neuropsychiatric diseases are as described above.
  • the method of treatment of the present invention comprises administering the pharmaceutical composition in a pharmaceutically effective amount in a subject suspected of neuropsychiatric disease.
  • the subject means an entire mammal including a dog, cow, horse, rabbit, mouse, rat, chicken or human, but the mammal of the present invention is not limited to the above examples.
  • the pharmaceutical composition may be administered orally, subcutaneously, intraperitoneally, pulmonary and intranasally, and may be administered by a suitable method including topical administration if necessary for local treatment.
  • Preferred dosages of the pharmaceutical compositions of the present invention vary depending on the condition and weight of the individual, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
  • the present invention provides a food composition for the prevention or improvement of neuropsychiatric diseases, including Acanthopanax koreanum extract as an active ingredient.
  • the extract of the present invention may be added to the food composition for the purpose of preventing or ameliorating neuropsychiatric diseases.
  • the sesame stem extract of the present invention When used as a food additive, the extract or a fraction thereof may be added as it is or used with other foods or ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient can be suitably determined depending on the intended use.
  • Examples of foods to which the island extract may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, tea, Drinks, alcoholic beverages and vitamin complexes, and the like, may include all foods in the conventional sense, and includes foods used as feed for animals.
  • the food composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And carbonic acid used in carbonated beverages. Others may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
  • the food may also be prepared in the form of tablets, granules, powders, capsules, liquid solutions and pills according to known production methods. There is no particular limitation on other components except that the sesame stem extract according to the present invention is included as an active ingredient, and various conventional flavoring agents or natural carbohydrates may be included as additional ingredients.
  • the present invention is an extract of the island of the snails; And it provides a method for producing a composition comprising the same.
  • the island and the island extract is as described above.
  • the preparation method is (a) 1 to 100 times (v / w) of the dry sesame stem sample weight, water of 1 to 6 carbon atoms or a mixed solvent thereof is added to 25 to 120 °C for 1 hour to Extracting for 8 hours; And (b) filtration, concentration under reduced pressure, and drying the water extracted in step (a).
  • the step (a) is the step of extracting from the islands using the extraction solvent, the islands of the pulverized pulpy extract using water, alcohol having 1 to 6 carbon atoms, preferably alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof Extraction step.
  • the extraction is preferably extracted by cold needle extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, ultra-high pressure extraction or heat extraction for 1 to 8 hours at 25 °C to 120 °C, the eleuteroside B of the present invention (eleutheroside B), eleutheroside E (eleutheroside E) and akanho (achanthoic acid) is a method for producing an extract containing an acid (achanthoic acid) is not particularly limited to those kinds.
  • Step (b) is a step of filtration, concentration under reduced pressure and drying the water extracted in step (a).
  • Isao gapi extract of the present invention through a manufacturing method comprising the above step; And it can be prepared a composition comprising the same.
  • the present invention provides a pharmaceutical composition for neuronal regeneration comprising an extract of Acanthopanax koreanum as an active ingredient.
  • sesame stem, sesame stem extract and the pharmaceutical composition are as described above.
  • nervegenesis refers to a process in which neurons are produced or regenerated from neural stem cells or progenitor cells.
  • nerve regeneration is involved in a protein such as DCX (Doublecortin), the degree of nerve regeneration can be confirmed through the level of DCX (Doublecortin) expression.
  • DCX Doublecortin
  • various neuropsychiatric diseases such as depression are known to reduce nerve regeneration in the hippocampus. Therefore, the extract of the island of the present invention which increases the expression level of DCX and brings nerve regeneration can be usefully used not only for nerve regeneration but also for the treatment of neuropsychiatric diseases.
  • the composition of the present invention for nerve regeneration when administering the composition containing the extract of the island of the present invention to a mouse having a reduced degree of nerve regeneration, it was confirmed that the DCX positive level is higher than the control group, the composition of the present invention for nerve regeneration It was confirmed that it can be used (Fig. 2, Experimental Example 1).
  • a food composition for nerve regeneration comprising an extract of Acanthopanax koreanum as an active ingredient.
  • the sumo gapi, iso gapi extract, nerve regeneration and the food composition is as described above.
  • the sesame stem extract of the present invention has neuronal regeneration activity, it can be usefully used as a food composition for neuronal regeneration.
  • ICR mice Six-week-old ICR mice (23-25 g) were supplied from Orient Co., Ltd. (Seoulm Korea) and used in animal experiments with 10-12 animals per group. The experimental animals were used in a clean cage for about 5 days, and the water and feed were freely consumed. The temperature (23 ⁇ 2 °C), humidity (55 ⁇ 10%) and contrast cycle (12 hours) It was adjusted automatically.
  • the sessipapi extract of the present invention has a neuronal regeneration effect, and furthermore, because it brings a neuronal regeneration effect in the nerve damage induced by stress, depression and anxiety disorders can be treated for stress, depression and anxiety disorders. It is suggestive.
  • the forced swimming test is one of the animal test methods to check the exercise activity and depression of the animals.
  • the EthoVision program fills a 30cm long transparent acrylic tube with about 25cm of water (about 24 °C) and displays the animal's behavior for 6 minutes. Observation was carried out by using.
  • Cruciform maze test is an experimental method to measure the degree of anxiety of an experimental animal by using an elevated plus-maze made of black acrylic.
  • the mouse is gently lowered toward the open space from the center of the maze. Placed and then freely navigated through the maze. At this time, the behavior is observed for 5 minutes, and the time of staying in the open and closed spaces of the mouse, the number of entrances and the total moving distance of each space are measured by the EthoVision program (Noldus Information Technology, Wageningen, Netherlands). The effect was confirmed. After administering orally to the isogapi extract obtained in Example 1 was measured for 10 animals in each group in a room where the noise is blocked after about 1 hour.
  • the sesame stem extract of the present invention can significantly improve anxiety due to stress.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a composition comprising an Acanthopanax koreanum extract as an active ingredient. More particularly, the present invention relates a pharmaceutical composition comprising the Acanthopanax koreanum extract for preventing or treating neuropsychiatric disorders, to a food composition comprising the Acanthopanax koreanum extract for preventing or alleviating neuropsychiatric disorders, to a method for preparing the composition, and to a pharmaceutical composition and food composition comprising the Acanthopanax koreanum extract for neuranagenesis.

Description

섬오가피 추출물을 유효성분으로 포함하는 신경정신 질환의 예방 또는 치료용 조성물A composition for the prevention or treatment of neuropsychiatric diseases comprising the extract of sesame stem as an active ingredient
본 발명은 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는 조성물에 관한 것으로, 구체적으로 섬오가피 추출물을 포함하는 신경정신 질환의 예방 또는 치료용 약학적 조성물, 섬오가피 추출물을 포함하는 신경정신질환의 예방 또는 개선용 식품 조성물, 상기 조성물의 제조방법 및; 섬오가피 추출물을 포함하는 신경재생용 약학적 조성물 및 식품 조성물에 관한 것이다.The present invention relates to a composition comprising an extract of Acanthopanax koreanum as an active ingredient, specifically, a pharmaceutical composition for the prevention or treatment of neuropsychiatric diseases including the extract of S. a. Food composition for the prevention or improvement of the method of preparing the composition; It relates to a pharmaceutical composition and a food composition for neuronal regeneration comprising an extract of the island stem.
섬오가피(Acanthopanax koreanum Nakai)는 오갈피나무속(Eleutherococcus) 수종으로 두릅나무과(Araliaceae)에 속하는 나무이다. 우리나라 제주도의 해발 1400m이하에서 자생하는 제주특산 수종으로 제주도산이라 하여 탐라오갈피 (Tamraukogi)라고도 부른다. 섬오가피의 꽃이 피는 시기는 5월이며, 열매가 익는 시기는 9월부터이다. 상기 섬오가피는 가시가 억세며 줄기가 땅에 늘어지는 습관이 있으며 성장력은 매우 왕성하다. 뿌리는 특유한 향기를 지니고 있으며 주근, 지근, 세근으로 나누어져 있다(Han K.J. et al., Growth of seeding and germination characteristics of Acanthopanax koreanum Nakai. Korean J. Medicinal Crop Sci. 11, 46-52, 2003, 임병선 외 2명, 지리산오갈피와 섬오갈피의 생육특성 및 자생지 식생조사, 한국자원식물학회지, 12, 125-132, 1999). Acanthopanax koreanum Nakai is an Eleutherococcus species and belongs to the family Araliaceae. It is a special species of Jeju that grows at 1400m above sea level of Jeju Island in Korea. It is also called Tamraukogi. The flowering period of the island is in May, and the ripening season begins in September. The islands have strong thorns and have a habit of stalks hanging on the ground, and growth is very vigorous. The roots have a distinctive fragrance and are divided into main root, root and root (Han KJ et al., Growth of seeding and germination characteristics of Acanthopanax koreanum Nakai.Korean J. Medicinal Crop Sci. 11, 46-52, 2003, Byung-Sun Lim And 2 others, Growth Characteristics and Botanical Vegetation Survey of Ogalpi Jiri and Island Ogalpi, Journal of the Plant Resources Society of Korea, 12, 125-132, 1999).
상기 섬오가피의 뿌리, 줄기 및 잎의 주요 성분으로는 배당체, 플라보노이드, 디테르페노이드(diterpenoid) 등이 있으며, 특히 뿌리에는 아칸토산(acanthoic acid) 성분이 대량 함유되어 있음이 알려져 있다(Lim, J.H. et al, Changes in major constituents by soaking of Acanthopanax koreanum with spirit solution. J. Korean Soc. Appl. Biol. Chem., 48, 166-172, 2005). 상기 섬오가피는 한국에서는 주로 뿌리를 이용하여 전통적으로 몸을 가볍게 하는 치료제로 쓰이고 있으며, 비만, 류마티즘, 당뇨병, 간염 등의 병증에 쓰이는 것으로 보고된 바 있다(Yang, E.J. et al. Acanthopanax koreanum fruit waste inhibits lipopolysaccharide-induced production of nitric oxide and prostaglandin E2 in RAW 264.7 macrophages. J. Biomed Biotechnol., 2010, 715-739, 2010).The main components of the roots, stems and leaves of the isogapi include glycosides, flavonoids, diterpenoids, and the like, and in particular, it is known that the root contains acanthoic acid (Lim, JH et al, Changes in major constituents by soaking of Acanthopanax koreanum with spirit solution.J. Korean Soc.Appl. Biol. Chem., 48, 166-172, 2005). The island ogapi is traditionally used as a therapeutic agent to lighten the body, mainly by using roots, and has been reported to be used for diseases such as obesity, rheumatism, diabetes and hepatitis (Yang, EJ et al. Acanthopanax koreanum fruit waste). inhibits lipopolysaccharide-induced production of nitric oxide and prostaglandin E2 in RAW 264.7 macrophages.J. Biomed Biotechnol., 2010, 715-739, 2010).
현대 생활의 소모적이고 바쁜 일상, 스트레스 등으로 인하여 우울증 및 불안장애 등과 같은 정신질환으로 진단 및 치료받는 환자의 숫자는 최근 수년간 급격히 증가하였으며, 향후에도 지속적으로 증가할 것으로 예상된다. 우울증은 흔한 질병으로 미국에서는 연간 약 1800만명 이상이 우울증으로 고생하고 있으며, 우리나라에서도 우울증의 평생 유병율은 전체인구의 15% 정도라고 알려져 있지만 국내 많은 환자들이 인식 부족 또는 정신질환에 대한 사회적 편견으로 인하여 항우울제 복용을 주저하고 있는 실정이다. 불안장애는 주로 불안한 감정으로 드러나는 정신계 질환으로서, 자율신경계 장애, 근육 경직, 운동장애 등과 같은 다양한 증상이 계속적으로 나타나는 긴장 정서로 일상생활 많은 부정적인 영향을 주고 있다. 그동안 정신질환 치료제의 연구개발은 대부분 GABA 신경계, 세로토닌(serotonin) 신경계, 노르아드레날린(noradrenaline) 신경계 및 뉴로펩타이드(neuropeptide) 계에 초점이 맞추어져 왔으며 이들 치료제는 불안장애와 우울증 개선에 많은 기여를 하였으나, 그 부작용 등으로 인해 사용에 많은 제한을 받고 있다. The number of patients diagnosed and treated for mental illnesses such as depression and anxiety disorders has increased rapidly in recent years due to the exhausting and busy daily life and stress of modern life. Depression is a common disease, and in the United States, more than 18 million people suffer from depression every year, and the lifetime prevalence of depression in Korea is known to be about 15% of the population, but many patients in Korea are suffering from lack of awareness or social prejudice against mental illness. Hesitant to take antidepressants. Anxiety disorder is a psychological disorder mainly manifested by anxiety emotions, and has a lot of negative effects on daily life due to tension emotions that continuously show various symptoms such as autonomic nervous system disorders, muscle stiffness, and motor disorders. In the past, research and development of psychiatric diseases have been focused on GABA nervous system, serotonin nervous system, noradrenaline nervous system and neuropeptide system. Due to its side effects, there are many restrictions.
이러한 배경 하에 본 발명자들은 우울증, 불안장애와 같은 다양한 정신 질환을 예방 및 치료하면서, 신경재생 효과를 가지는 천연물을 찾기 위하여 예의 노력한 결과, 오가피 속 식물 중에서도 섬오가피 추출물이 높은 신경재생효과, 항우울 및 항불안 활성을 가짐을 확인하고, 본 발명을 완성하였다.Against this backdrop, the present inventors have made diligent efforts to find natural products having a neurological regeneration effect while preventing and treating various mental disorders such as depression and anxiety disorder. It was confirmed that the anti-anxiety activity, and completed the present invention.
본 발명의 하나의 목적은 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경정신 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다. One object of the present invention to provide a pharmaceutical composition for the prevention or treatment of neuropsychiatric disorders, including Acanthopanax koreanum extract as an active ingredient.
본 발명의 다른 목적은 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경정신 질환의 예방 또는 개선용 식품 조성물을 제공하는 것이다.It is another object of the present invention to provide a food composition for preventing or improving neuropsychiatric diseases, comprising an extract of Acanthopanax koreanum as an active ingredient.
본 발명의 또 다른 목적은 신경정신 질환 의심 개체에 상기 약학적 조성물을 투여하는 단계를 포함하는, 신경 정신 질환의 치료방법을 제공하는 것이다.Still another object of the present invention is to provide a method of treating neuropsychiatric disorders, comprising administering the pharmaceutical composition to an individual suspected of neuropsychiatric disorders.
본 발명의 또 다른 목적은 상기 조성물의 제조방법을 제공하는 것이다. Still another object of the present invention is to provide a method for preparing the composition.
본 발명의 또 다른 목적은 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경재생용 약학적 조성물을 제공하는 것이다.Still another object of the present invention is to provide a pharmaceutical composition for nerve regeneration, comprising an extract of Acanthopanax koreanum as an active ingredient.
본 발명의 또 다른 목적은 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경재생용 식품 조성물을 제공하는 것이다.Still another object of the present invention is to provide a neurological regeneration food composition comprising an extract of Acanthopanax koreanum as an active ingredient.
본 발명의 섬오가피 추출물은 오랫동안 천연약재로 사용되어온 천연물에서 유래되어 부작용이 없으면서도 우울증, 불안 장애와 같은 신경 정신 질환에 대한 치료 효과; 및 신경 재생 효과를 가지므로, 섬오가피 추출물을 포함하는 본 발명의 조성물은 신경 정신 질환의 예방 또는 치료; 및 신경 재생이 필요한 분야에 있어 유용하게 사용될 수 있다.Seogagapi extract of the present invention is derived from a natural product that has been used as a natural medicine for a long time without the side effects, but also a therapeutic effect against neuropsychiatric diseases such as depression, anxiety disorders; And because it has a nerve regeneration effect, the composition of the present invention comprising isogapi extract is used for the prevention or treatment of neuropsychiatric diseases; And neural regeneration.
도 1은, 본 발명의 실시예에 따른 섬오가피 추출물의 제조 방법을 도시한 흐름도이다.1 is a flow chart illustrating a method for preparing sesame stem extract according to an embodiment of the present invention.
도 2는, 본 발명의 섬오가피 추출물을 투여한 생쥐에 뇌의 신경재생성을 대조군과 비교한 그래프이다.Figure 2 is a graph comparing the neuronal regeneration of the brain in the mice administered the extract of the island of the present invention compared with the control.
도 3은, 본 발명의 섬오가피 추출물을 투여한 생쥐에 대한 강제수영검사에 있어서 부동 시간을 대조군과 비교한 그래프이다.Figure 3 is a graph comparing the immobility time with the control group in the forced swimming test for the mice administered the isogapi extract of the present invention.
도 4는, 본 발명의 섬오가피 추출물을 투여한 생쥐에 대한 상승된 십자미로의 열린 공간에 머무른 시간을 대조군과 비교한 그래프이다.Figure 4 is a graph comparing the time spent in the open space in the raised cruciform with the control mice for the mice administered the isogapi extract of the present invention.
상기의 목적을 달성하기 위한 하나의 양태로서, 본 발명은 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경정신 질환의 예방 또는 치료용 약학적 조성물을 제공한다.As one aspect for achieving the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of neuropsychiatric diseases, including Acanthopanax koreanum extract as an active ingredient.
본 발명에서 용어, "섬오가피(Acanthopanax koreanum)"는 오갈피나무속(Eleutherococcus) 수종으로 두릅나무과(Araliaceae)에 속하는 나무를 의미하며, 상기 섬오가피는 탐라오갈피 등과 혼용될 수 있다. 섬오가피는 잎, 줄기, 뿌리 및 열매로 나누어져 있으며, 특히 뿌리는 주근, 지근, 세근으로 나누어져 있다. 상기 섬오가피는 간질환, 항염증 및 면역력을 증강시키는 것으로 알려져 있으나, 신경 정신 질환에의 효능은 알려진 바 없으며, 본 발명자들에 의해 새롭게 규명되었다. 상기 섬오가피는 자연에서 채취한 것을 사용하거나 상업적으로 판매되는 것을 구입할 수 있으나, 이에 제한되지 않는다. In the present invention, the term " Acanthopanax koreanum " refers to a tree belonging to the family Araliaceae as an Eleutherococcus species, and the island canopy can be used interchangeably with tamra orgapi. Seogagapi is divided into leaves, stems, roots, and fruits, and the roots are divided into main roots, roots, and roots. The isogapi is known to enhance liver disease, anti-inflammatory and immunity, but the efficacy on neuropsychiatric diseases is not known, it was newly identified by the present inventors. The islands can be used in nature or purchased commercially available, but is not limited thereto.
본 발명에서 용어, "섬오가피(Acanthopanax koreanum) 추출물"은 섬오가피를 추출하여 수득한 추출물을 의미한다. 본 발명에서 상기 섬오가피 추출물은 바람직하게는 섬오가피의 뿌리 또는/및 줄기를 추출하여 수득한 추출물을 의미한다. 상기 섬오가피 추출물은 섬오가피 분쇄물을 물, 탄소수 1 내지 6의 알코올, 바람직하게는 탄소수 1 내지 4의 알코올, 또는 이들의 혼합용매를 이용하여 추출하여 제조할 수 있고, 바람직하게는 25℃ 내지 120℃에서 1시간 내지 8시간 동안 냉침 추출, 열수 추출, 초음파 추출, 환류냉각 추출, 초고압 추출 또는 가열 추출법으로 추출할 수 있으나, 신경 정신 질환에 대한 치료 효과 또는 신경재생 효과를 가지는 물질을 추출하는 방법이라면 그 종류에 특별히 제한되지 않는다. 상기 추출과정을 거친 물은 여과, 감압농축 및 건조 과정을 순차적으로 거쳐 본 발명의 추출물로 제조될 수 있으나, 특별히 이에 제한되지 않고, 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 이들의 조정제물 또는 정제물을 모두 포함한다. 또한, 상기 섬오가피 추출물은 천연, 잡종, 변종 식물의 다양한 기관으로부터 추출될 수 있다. 본 발명의 일 실시예에서는 섬오가피의 뿌리 및 줄기로부터 70% 에탄올을 이용하여 추출하였다(실시예 1).As used herein, the term " acanthopanax koreanum extract" refers to an extract obtained by extracting isopipi. In the present invention, the island extract is preferably an extract obtained by extracting the root or / and stem of the island. The sesame stem extract may be prepared by extracting the sesame stem pulverized product using water, an alcohol having 1 to 6 carbon atoms, preferably an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. Extracted by cold needle extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, ultra-high pressure extraction or heat extraction for 1 to 8 hours at 120 ℃, but extracts a substance having a therapeutic effect or neuroregeneration effect for neuropsychiatric diseases If the method is not particularly limited to the kind. Water after the extraction process may be prepared as an extract of the present invention through filtration, concentrated under reduced pressure and drying in sequence, without being particularly limited thereto, extracts, dilutions or concentrates of extracts, dried products obtained by drying the extracts, or All these modifiers or purified products are included. In addition, the sesame stem extract can be extracted from various organs of natural, hybrid, varieties of plants. In one embodiment of the present invention was extracted using 70% ethanol from the roots and stems of the island stem (Example 1).
본 발명의 섬오가피 추출물은 엘레우테로사이드 B(eleutheroside B), 엘레우테로사이드 E(eleutheroside E) 및 아칸산(achanthoic acid)으로 이루어지는 군으로부터 선택되는 하나 이상의 성분을 포함하는 것을 특징으로 한다.Seogagapi extract of the present invention is characterized in that it comprises at least one component selected from the group consisting of eleutheroside B (eleutheroside B), eleutheroside E (eleutheroside E) and achanthoic acid.
본 발명에서 용어, "엘레우테로사이드 B(eleutheroside B)"는 시린긴(syringin)으로도 명명되는 페닐 프로파노이드 글리코사이드로서, 하기 화학식 1의 구조를 가진다.As used herein, the term "eleutheroside B" refers to a phenyl propanoid glycoside, also named syringin, and has a structure represented by the following Chemical Formula 1.
화학식 1
Figure PCTKR2013003257-appb-C000001
Formula 1
Figure PCTKR2013003257-appb-C000001
본 발명에서 용어, "엘레우테로사이드 E(eleutheroside E)"는 아칸토사이드 D(Acanthoside D)로 명명되는 글루코사이드 화합물로서, 하기 화학식 2의 구조를 가진다. 상기 엘레우테로사이드 E는 간 보호 활성, 해독 작용 등을 가지는 것으로 알려져 있다.As used herein, the term "eleutheroside E" refers to a glucoside compound named Acanthoside D and has a structure represented by the following Chemical Formula 2. The eleuteroside E is known to have hepatoprotective activity, detoxification effect and the like.
화학식 2
Figure PCTKR2013003257-appb-C000002
Formula 2
Figure PCTKR2013003257-appb-C000002
본 발명에서 용어, "아칸토산(acanthoic acid)"은 섬오갈피나무의 근피 성분으로서, 강력한 진통 억제, 항염 활성, 면역 체계의 항상성 유지 등의 활성을 가지고 있는 것으로 알려져 있으며, 하기 화학식 3의 구조를 가진다.As used herein, the term "acanthoic acid" is known to have potent analgesic components, such as potent analgesic suppression, anti-inflammatory activity, and maintenance of the homeostasis of the immune system. Have
화학식 3
Figure PCTKR2013003257-appb-C000003
Formula 3
Figure PCTKR2013003257-appb-C000003
상기와 같은 엘레우테로사이드 B, 엘레우테로사이드 E 및 아칸토산을 포함하는 본 발명의 섬오가피 추출물은 신경재생, 항불안 및 항우울활성을 지니므로, 다양한 신경 정신 질환의 예방 또는 치료에 있어 유용하게 사용될 수 있다. Since the isogapi extract of the present invention comprising the above eleuteroside B, eleuteroside E and acantosan has neuronal regeneration, anti-anxiety and antidepressant activity, in the prevention or treatment of various neuropsychiatric diseases It can be usefully used.
본 발명에서 용어, "신경 정신 질환"은 신경세포의 발달 저하 등에 의하여 야기될 수 있는 정신 질환을 의미한다. 본 발명의 목적상 상기 신경 정신 질환은 본 발명의 섬오가피 추출물에 의하여 치료될 수 있는 장애(anxiety), 우울증(depression) 또는 정동 장애(affective disorder)를 포함한다. 상기 불안장애는 비정상적, 병적인 불안과 공포로 인하여 일상 생활에 장애를 일으키는 정신 질환을 의미하며, 상기 우울증은 의욕 저하와 우울감을 그 주요 증상으로 하는 질환으로 다양한 인지 및 정신 신체적 증상을 일으켜 일상 기능의 저하를 가져오는 질환을 의미한다. 상기 정동 장애는 기분이 너무 좋거나 우울한 것을 주요 증상으로 하는 신경 정신 질환의 일종을 의미한다.As used herein, the term "neuropsychiatric disorder" means a mental disorder that may be caused by the development of neurons, and the like. For the purposes of the present invention, the neuropsychiatric disorders include anxiety, depression or affective disorders that can be treated by the extract of sesame stem of the present invention. The anxiety disorder refers to a mental illness that causes disorders in daily life due to abnormal and pathological anxiety and fear, and the depression is a disorder in which motivation and depression are the main symptoms, causing various cognitive and mental and physical symptoms, thereby causing daily functions. Means a disease that brings down the. The affective disorder refers to a type of neuropsychiatric disorder whose main symptom is moody or depressed mood.
본 발명에서 용어, "예방"은 상기 조성물의 투여에 의해 신경 정신 질환을 억제하거나 발병을 지연시키는 모든 행위를 의미하며, "치료"는 상기 조성물의 투여에 의해 신경 정신 질환에 의한 증세가 호전되거나 이롭게 변경되는 모든 행위를 의미한다.As used herein, the term "prevention" refers to any action that inhibits or delays the onset of neuropsychiatric disorders by the administration of the composition, and "treatment" means that symptoms caused by neuropsychiatric disorders are improved by administration of the composition. It means any action that is beneficially changed.
본 발명의 섬오가피 추출물을 포함하는 약학적 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형체 또는 희석제를 추가로 포함할 수 있다. 이때, 상기 조성물에 포함되는 추출물 또는 이의 분획물의 함량은 특별히 이에 제한되지 않으나, 조성물 총 중량에 대하여 0.0001 중량% 내지 99.99중량%로, 바람직하게는 0.001 중량% 내지 50 중량%를 포함할 수 있다.The pharmaceutical composition comprising the sesame stem extract of the present invention may further comprise a suitable carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition. At this time, the content of the extract or fractions thereof included in the composition is not particularly limited, but may be 0.0001% to 99.99% by weight, preferably 0.001% to 50% by weight based on the total weight of the composition.
상기 약학적 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제 및 좌제으로 이루어진 군으로부터 선택되는 어느 하나의 제형을 가질 수 있으며, 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테로 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have one formulation and can be a variety of oral or parenteral formulations. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 조성물은 약학적으로 유효한 양으로 투여할 수 있다.The composition of the present invention may be administered in a pharmaceutically effective amount.
본 발명에서 용어, "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 질병의 종류, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다. 그러나 바람직한 효과를 위해서는 본 발명의 약학 조성물은 1일 0.001 내지 100㎍/kg으로, 더욱 바람직하게는 0.01 내지 100㎍/㎏의 범위로 비경구 또는 경구 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면에서든 본 발명의 범위를 한정하는 것은 아니다.상기 조성물은 쥐, 가축, 인간 등의 다양한 포유동물에 다양한 경로로 투여할 수 있으며, 투여의 방식은 당업계의 통상적인 방법이라면 제한없이 포함하며, 예를 들어, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다.As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type and severity, age, sex, disease of the individual. It may be determined according to the type, activity of the drug, sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical field. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art. However, for the desired effect, the pharmaceutical composition of the present invention is preferably administered parenterally or orally in the range of 0.001 to 100 µg / kg, more preferably in the range of 0.01 to 100 µg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the present invention in any aspect. The composition may be administered to various mammals such as rats, livestock, humans, etc. by various routes, and the mode of administration may be any conventional method in the art. Without limitation, it may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections.
본 발명의 일 실시예에서는 섬오가피의 뿌리 및 줄기로부터 70% 에탄올을 이용하여 섬오가피 추출물을 제조하였고, 섬오가피 추출물이 스트레스가 유발된 뇌 내의 해마 영역의 신경 재생 효과를 가짐을 확인하였다(도 2, 실험예 1). 또한 본 발명의 섬오가피 추출물이 생쥐 강제 수영법을 통하여 항우울 활성을 가짐을 확인하여, 본 발명의 조성물이 신경 정신 질환의 일종인 우울증의 치료에 유용하게 사용될 수 있음을 확인하였다(도 3, 실험예 2). 뿐만 아니라, 본 발명의 섬오가피 추출물이 십자 미로 시험에서 열린 공간에 머무르는 시간을 증가시키는 것을 확인하여 불안 장애의 예방 및 치료에 유용함을 확인하였다(도 4, 실험예 3).In one embodiment of the present invention was prepared from the root and stem of the sesame stem using 70% ethanol extract was confirmed that the sesame stem extract has a neuronal regeneration effect in the hippocampal region in the stress-induced brain (Fig. 2, Experimental Example 1). In addition, it was confirmed that the sesame stem extract of the present invention has antidepressant activity through the forced swimming method of the mouse, and thus the composition of the present invention can be usefully used for the treatment of depression, which is a kind of neuropsychiatric disease (FIG. 3, Experimental Example 2). In addition, it was confirmed that the sesame stem extract of the present invention increases the time to stay in the open space in the cross maze test, it is useful for the prevention and treatment of anxiety disorder (Fig. 4, Experimental Example 3).
또 다른 양태로서, 본 발명은 신경 정신 질환 의심 개체에 상기 조성물을 투여하는 단계를 포함하는, 신경 정신 질환의 치료 방법을 제공한다.In another aspect, the present invention provides a method of treating neuropsychiatric disorders comprising administering the composition to a subject suspected of neuropsychiatric disorders.
상기 조성물 및 신경 정신 질환에 대해서는 상기에서 설명한 바와 같다.The composition and neuropsychiatric diseases are as described above.
구체적으로, 본 발명의 치료 방법은 상기 약학적 조성물을 약학적 유효량으로 신경 정신 질환 의심 개체 내에 투여하는 것을 포함한다. 상기 개체는 개, 소, 말, 토끼, 마우스, 랫트, 닭 또는 인간을 포함하는 포유류 전체를 의미하나, 상기 예에 의해 본 발명의 포유류가 한정되는 것은 아니다. 상기 약학적 조성물은 비 경구, 피하, 복강 내, 폐 내 및 비강 내로 투여될 수 있고, 국부적 치료를 위해, 필요하다면 병변 내 투여를 포함하는 적합한 방법에 의하여 투여될 수 있다. 본 발명의 상기 약학적 조성물의 바람직한 투여량은 개체의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.Specifically, the method of treatment of the present invention comprises administering the pharmaceutical composition in a pharmaceutically effective amount in a subject suspected of neuropsychiatric disease. The subject means an entire mammal including a dog, cow, horse, rabbit, mouse, rat, chicken or human, but the mammal of the present invention is not limited to the above examples. The pharmaceutical composition may be administered orally, subcutaneously, intraperitoneally, pulmonary and intranasally, and may be administered by a suitable method including topical administration if necessary for local treatment. Preferred dosages of the pharmaceutical compositions of the present invention vary depending on the condition and weight of the individual, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
또 다른 양태로서, 본 발명은 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경정신 질환의 예방 또는 개선용 식품 조성물을 제공한다.In another aspect, the present invention provides a food composition for the prevention or improvement of neuropsychiatric diseases, including Acanthopanax koreanum extract as an active ingredient.
상기 섬오가피, 추출물 및 신경정신 질환에 대해서는 상기에서 설명한 바와 같다. The islands, extracts and neuropsychiatric diseases are as described above.
구체적으로, 본 발명의 추출물은 신경 정신 질환의 예방 또는 개선을 목적으로 식품 조성물에 첨가할 수 있다. Specifically, the extract of the present invention may be added to the food composition for the purpose of preventing or ameliorating neuropsychiatric diseases.
본 발명의 섬오가피 추출물을 식품 첨가물로 사용할 경우, 상기 추출물 또는 이의 분획물을 그대로 첨가하거나 다른 식품 또는 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합량은 사용 목적에 따라 적합하게 결정할 수 있다. When the sesame stem extract of the present invention is used as a food additive, the extract or a fraction thereof may be added as it is or used with other foods or ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient can be suitably determined depending on the intended use.
또한, 본 발명의 식품의 종류에는 특별한 제한은 없다. 상기 섬오가피 추출물을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있고, 통상적인 의미에서의 식품을 모두 포함할 수 있으며, 동물을 위한 사료로 이용되는 식품을 포함한다.In addition, there is no particular limitation on the type of food of the present invention. Examples of foods to which the island extract may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, tea, Drinks, alcoholic beverages and vitamin complexes, and the like, may include all foods in the conventional sense, and includes foods used as feed for animals.
상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄 산화제 등을 함유할 수 있다. 그밖에 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 또한, 상기 식품은 공지의 제조방법에 따라 정제, 과립, 분말, 캅셀, 액상의 용액 및 환 등의 제형으로도 제조될 수 있다. 본 발명에 의한 섬오가피 추출물을 유효성분으로 포함하는 것 이외에는 다른 성분에는 특별한 제한이 없으며, 통상의 여러가지 향미제 또는 천연 탄수화물 등을 추가성분으로 포함할 수 있다. In addition to the above, the food composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And carbonic acid used in carbonated beverages. Others may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. In addition, the food may also be prepared in the form of tablets, granules, powders, capsules, liquid solutions and pills according to known production methods. There is no particular limitation on other components except that the sesame stem extract according to the present invention is included as an active ingredient, and various conventional flavoring agents or natural carbohydrates may be included as additional ingredients.
또 다른 양태로서, 본 발명은 상기 섬오가피 추출물; 및 이를 포함하는 조성물의 제조방법을 제공한다. In another embodiment, the present invention is an extract of the island of the snails; And it provides a method for producing a composition comprising the same.
상기 섬오가피 및 섬오가피 추출물에 대해서는 상기에서 설명한 바와 같다. The island and the island extract is as described above.
구체적으로, 상기 제조방법은 (a) 건조한 섬오가피 시료 중량의 1 내지 100배(v/w)의 물, 탄소수 1 내지 6의 알코올 또는 이들의 혼합 용매를 가하여 25℃ 내지 120℃에서 1시간 내지 8시간 동안 추출하는 단계; 및 (b) 상기 (a) 단계에서 추출한 물을 여과, 감압농축 및 건조하는 단계를 포함한다.Specifically, the preparation method is (a) 1 to 100 times (v / w) of the dry sesame stem sample weight, water of 1 to 6 carbon atoms or a mixed solvent thereof is added to 25 to 120 ℃ for 1 hour to Extracting for 8 hours; And (b) filtration, concentration under reduced pressure, and drying the water extracted in step (a).
상기 (a) 단계는 추출 용매를 이용하여 섬오가피로부터 추출하는 단계로서, 섬오가피 분쇄물을 물, 탄소수 1 내지 6의 알코올, 바람직하게는 탄소수 1 내지 4의 알코올, 또는 이들의 혼합용매를 이용하여 추출하는 단계이다. 상기 추출은 바람직하게는 25℃ 내지 120℃에서 1시간 내지 8시간 동안 냉침 추출, 열수 추출, 초음파 추출, 환류냉각 추출, 초고압 추출 또는 가열 추출법으로 추출할 수 있으나, 본 발명의 엘레우테로사이드 B(eleutheroside B), 엘레우테로사이드 E(eleutheroside E) 및 아칸산(achanthoic acid)을 포함하는 추출물을 제조하는 방법이라면 특별히 그 종류에 제한되지 않는다. The step (a) is the step of extracting from the islands using the extraction solvent, the islands of the pulverized pulpy extract using water, alcohol having 1 to 6 carbon atoms, preferably alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof Extraction step. The extraction is preferably extracted by cold needle extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, ultra-high pressure extraction or heat extraction for 1 to 8 hours at 25 ℃ to 120 ℃, the eleuteroside B of the present invention (eleutheroside B), eleutheroside E (eleutheroside E) and akanho (achanthoic acid) is a method for producing an extract containing an acid (achanthoic acid) is not particularly limited to those kinds.
상기 (b) 단계는 (a) 단계에서 추출한 물을 여과, 감압농축 및 건조하는 단계이다.Step (b) is a step of filtration, concentration under reduced pressure and drying the water extracted in step (a).
상기 단계를 포함하는 제조방법을 통하여 본 발명의 섬오가피 추출물; 및 이를 포함하는 조성물을 제조할 수 있다.Isao gapi extract of the present invention through a manufacturing method comprising the above step; And it can be prepared a composition comprising the same.
또 다른 양태로서, 본 발명은 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경재생용 약학적 조성물을 제공한다.In another aspect, the present invention provides a pharmaceutical composition for neuronal regeneration comprising an extract of Acanthopanax koreanum as an active ingredient.
상기 섬오가피, 섬오가피 추출물 및 약학적 조성물에 대해서는 상기에서 설명한 바와 같다.The sesame stem, sesame stem extract and the pharmaceutical composition are as described above.
본 발명에서 용어, "신경재생(neurogenesis)"은 신경 줄기세포 또는 전구세포로 부터 뉴론이 생성 또는 재생되는 과정을 의미한다. 이와 같은 신경 재생에는 DCX(Doublecortin)와 같은 단백질이 관여하며, DCX(Doublecortin) 발현 수준을 통하여 신경 재생 정도를 확인할 수 있다. 또한, 우울증(depression)과 같은 다양한 신경 정신 질환 등은 해마의 신경 재생을 감소시키는 것으로 알려져 있다. 따라서, DCX의 발현 수준을 높이며 신경 재생을 가져오는 본 발명의 섬오가피 추출물은 신경 재생 뿐만 아니라, 나아가 신경 정신 질환의 치료에도 유용하게 사용될 수 있다. As used herein, the term "neurogenesis" refers to a process in which neurons are produced or regenerated from neural stem cells or progenitor cells. Such nerve regeneration is involved in a protein such as DCX (Doublecortin), the degree of nerve regeneration can be confirmed through the level of DCX (Doublecortin) expression. In addition, various neuropsychiatric diseases such as depression are known to reduce nerve regeneration in the hippocampus. Therefore, the extract of the island of the present invention which increases the expression level of DCX and brings nerve regeneration can be usefully used not only for nerve regeneration but also for the treatment of neuropsychiatric diseases.
본 발명의 일 실시예에서는 신경 재생 정도가 감소된 마우스에 본 발명의 섬오가피 추출물을 포함하는 조성물을 투여하는 경우, 대조군에 비하여 DCX 양성 수준이 높은 것을 확인하여, 본 발명의 조성물이 신경 재생에 사용될 수 있음을 확인하였다(도 2, 실험예 1).In one embodiment of the present invention, when administering the composition containing the extract of the island of the present invention to a mouse having a reduced degree of nerve regeneration, it was confirmed that the DCX positive level is higher than the control group, the composition of the present invention for nerve regeneration It was confirmed that it can be used (Fig. 2, Experimental Example 1).
또 다른 양태로서, 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경재생용 식품 조성물을 제공한다. In another aspect, it provides a food composition for nerve regeneration comprising an extract of Acanthopanax koreanum as an active ingredient.
상기 섬오가피, 섬오가피 추출물, 신경재생 및 식품 조성물에 대해서는 상기에서 설명한 바와 같다. The sumo gapi, iso gapi extract, nerve regeneration and the food composition is as described above.
본 발명의 섬오가피 추출물은 신경재생 활성을 지니므로, 신경재생용 식품 조성물로서 유용하게 이용될 수 있다.Since the sesame stem extract of the present invention has neuronal regeneration activity, it can be usefully used as a food composition for neuronal regeneration.
이하 본 발명을 하기 예에 의해 상세히 설명한다. 다만, 하기 예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by the following examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following examples.
실시예 1: 섬오가피 추출물 제조Example 1 Preparation of Seogagapi Extract
제주에서 구입한 건조된 섬오가피 줄기 및 뿌리 20kg에 10 내지 20배(v/w)의 70% 에탄올 수용액을 가하여 추출장치에서 70℃로 3 내지 5시간 동안 환류 추출하였다. 추출이 완료된 후 하우징 필터로 여과하고 감압농축 및 동결건조하여 섬오가피 추출물 1kg을 수득하여 하기 실험예의 시료로 사용하였다.10 to 20-fold (v / w) of 70% ethanol aqueous solution was added to 20 kg of dried island stems and roots purchased from Jeju, and refluxed at 70 ° C. for 3 to 5 hours in an extractor. After the extraction was completed, filtered through a housing filter, concentrated under reduced pressure and lyophilized to obtain 1 kg of sesame stem extract, which was used as a sample of the following experimental example.
실시예 2: 실험동물 준비Example 2: Experimental Animal Preparation
6주령의 ICR 생쥐 (23-25g)을 ㈜ 오리엔트(Seoulm Korea)에서 공급받아 그룹당 10 내지 12마리로 동물실험에 사용하였다. 실험동물은 소독 케이지(clean cage)에 약 5일간 적응시켜 사용하였으며, 물과 사료는 자유롭게 섭취하도록 하였고, 온도(23±2℃), 습도 (55±10%) 및 명암주기 (12시간)는 자동으로 조절되도록 하였다.Six-week-old ICR mice (23-25 g) were supplied from Orient Co., Ltd. (Seoulm Korea) and used in animal experiments with 10-12 animals per group. The experimental animals were used in a clean cage for about 5 days, and the water and feed were freely consumed. The temperature (23 ± 2 ℃), humidity (55 ± 10%) and contrast cycle (12 hours) It was adjusted automatically.
실험예 1: 뇌의 해마영역 면역염색법에 의한 신경재생성 확인Experimental Example 1: Confirmation of neuronal regeneration by hippocampal immunostaining
다양한 스트레스, 우울증 및 불안장애는 두뇌의 신경 재생성을 감소시키므로, 섬오가피 추출물의 뇌 내의 해마의 영역의 신경재생성 촉진에 미치는 영향을 확인하기 위하여 스트레스를 유도한 동물에 섬오가피 추출물을 장기 투여 한 다음, 신경재생성 효과를 면역염색법을 통하여 신경발생(neurogenesis) 마커인 DCX(Doublecortin)를 염색하여 확인하였다. Various stresses, depressions and anxiety disorders reduce the neuronal regeneration in the brain, so long-term administration of the extracts of the islands to stress-induced animals to determine the effect of the extracts on the promotion of neuronal regeneration in the hippocampus , The neuronal regeneration effect was confirmed by staining DCX (Doublecortin), a neurogenesis marker through immunostaining.
스트레스를 유도한 동물에게 섬오가피 추출물을 장기 투여 후 신경재생성을 확인한 결과, 도 2에 나타난 바와 같이 대조군인 스트레스 군과 비교하였을 시 100mg/kg 용량에서 DCX positive 세포의 수가 증가하는 것을 확인할 수 있었다. As a result of confirming the neuronal regeneration after long-term administration of isogapi extract to stress-induced animals, it was confirmed that the number of DCX positive cells increased at a dose of 100 mg / kg when compared to the control group as shown in FIG.
상기와 같은 결과는 본 발명의 섬오가피 추출물은 신경 재생 효과를 가지며, 나아가 스트레스, 우울증 및 불안장애로 유도된 신경 손상에 있어 신경 재생 효과를 가져오므로 스트레스, 우울증 및 불안장애를 치료할 수 있음을 시사하는 것이다.The results as described above is that the sessipapi extract of the present invention has a neuronal regeneration effect, and furthermore, because it brings a neuronal regeneration effect in the nerve damage induced by stress, depression and anxiety disorders can be treated for stress, depression and anxiety disorders. It is suggestive.
실험예 2: 강제수영법에 의한 항우울 활성 확인Experimental Example 2: Confirmation of antidepressant activity by forced swimming method
강제수영실험은 실험동물의 운동 활성 및 우울 정도를 검사하는 동물실험법 중 하나로서, 30cm 길이의 투명한 아크릴로 된 관에 약 25cm 정도의 물(약 24℃)을 채우고 6분간 동물의 행동을 EthoVision 프로그램을 이용하여 관찰하여 수행하였다.The forced swimming test is one of the animal test methods to check the exercise activity and depression of the animals. The EthoVision program fills a 30cm long transparent acrylic tube with about 25cm of water (about 24 ℃) and displays the animal's behavior for 6 minutes. Observation was carried out by using.
실험동물의 전혀 움직이지 않은 상태(immobility time), 오르는 상태(climbing time)가 증가하게 되면 삶에 대한 의지가 약한 것으로 판단하고, 감소할수록 삶의 의지가 매우 강한 것으로 판단하였다. When the immobility time and the climbing time of the test animals were increased, the determination of life was weak, and as it decreased, the determination of life was very strong.
상기 실시예 1에서 수득한 섬오가피 추출물을 동물에 경구로 투여하고 약 1시간 경과 후, 소음이 차단된 방에서 각 군당 10마리씩 측정하였다.About 1 hour after orally administering the isogapi extract obtained in Example 1 to the animals, 10 animals were measured for each group in a room where noise was blocked.
그 결과, 도 3에 나타낸 바와 같이, 모든 용량(25, 50, 100, 및 200mg/kg)에서 부동시간이 감소하는 것을 확인하였다. 상기와 같은 결과는 본 발명의 섬오가피 추출물의 투여가 항우울 활성을 지님을 시사하는 것이다. As a result, as shown in Figure 3, it was confirmed that the dead time is reduced at all doses (25, 50, 100, and 200 mg / kg). The above results suggest that the administration of the sesame stem extract of the present invention has antidepressant activity.
실험예 3: 상승된 십자 미로시험에 의한 항불안 활성 확인Experimental Example 3: Confirmation of anti-anxiety activity by elevated cross maze test
십자 미로시험은 검정색의 아크릴로 제작된 상승된 십자미로(elevated plus-maze)를 이용하여 실험동물의 불안 정도를 측정하는 실험방법으로, 마우스는 미로의 중앙에서 열린 공간 쪽으로 머리를 향하게 하여 살며시 내려놓은 다음 미로를 자유롭게 탐색하도록 하여 수행하였다. 이때, 행동은 5분간 관찰하며, 마우스가 열려 있는 공간과 닫혀 있는 공간에 머문 시간, 각 공간의 출입 횟수 및 총 이동거리 등을 EthoVision 프로그램(Noldus Information Technology, Wageningen, Netherlands)으로 각각 측정하여 항불안 효과를 확인하였다. 실시예 1에서 수득한 섬오가피 추출물을 동물에 경구로 투여하고 약 1시간 경과 후에 소음이 차단된 방에서 각 군당 10마리씩 측정하였다.Cruciform maze test is an experimental method to measure the degree of anxiety of an experimental animal by using an elevated plus-maze made of black acrylic. The mouse is gently lowered toward the open space from the center of the maze. Placed and then freely navigated through the maze. At this time, the behavior is observed for 5 minutes, and the time of staying in the open and closed spaces of the mouse, the number of entrances and the total moving distance of each space are measured by the EthoVision program (Noldus Information Technology, Wageningen, Netherlands). The effect was confirmed. After administering orally to the isogapi extract obtained in Example 1 was measured for 10 animals in each group in a room where the noise is blocked after about 1 hour.
그 결과, 스트레스 군과 비교하여 100, 200mg/kg 농도에서 열림 공간에 머무름 시간이 유의하게 증가하는 것을 확인하였다. 상기와 같은 결과는 본 발명의 섬오가피 추출물이 스트레스로 인한 불안을 현저히 개선시킬 수 있음을 시사하는 결과이다.As a result, it was confirmed that the retention time in the open space significantly increased at concentrations of 100 and 200 mg / kg compared to the stress group. The above results suggest that the sesame stem extract of the present invention can significantly improve anxiety due to stress.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art will appreciate that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. In this regard, the embodiments described above are to be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the following claims and equivalent concepts rather than the detailed description are included in the scope of the present invention.

Claims (11)

  1. 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경정신 질환의 예방 또는 치료용 약학적 조성물. Acanthopanax koreanum ( Acanthopanax koreanum ) comprising an extract as an active ingredient, a pharmaceutical composition for the prevention or treatment of neuropsychiatric diseases.
  2. 제1항에 있어서, 상기 섬오가피 추출물은 섬오가피의 뿌리, 줄기 또는 둘 다에서 추출한 것인 조성물.The composition of claim 1, wherein the sesame stem extract is extracted from the roots, stems, or both of the sesame stem.
  3. 제1항에 있어서, 상기 섬오가피 추출물은 물, 탄소수 1 내지 6의 알코올 또는 이들의 혼합용매로 추출한 것인 조성물.The composition of claim 1, wherein the island extract is extracted with water, alcohol having 1 to 6 carbon atoms, or a mixed solvent thereof.
  4. 제1항에 있어서, 상기 섬오가피 추출물은 엘레우테로사이드 B(eleutheroside B), 엘레우테로사이드 E(eleutheroside E) 및 아칸토산(acanthoic acid)을 포함하는 것을 특징으로 하는 것인 조성물.The composition of claim 1, wherein the isogapi extract comprises eleutheroside B, eleutheroside E, and acanthoic acid.
  5. 제1항에 있어서, 상기 신경정신 질환은 불안장애(anxiety), 우울증(depression) 또는 정동 장애(affective disorder)인 것인 조성물.The composition of claim 1, wherein the neuropsychiatric disorder is anxiety, depression or affective disorder.
  6. 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경정신 질환의 예방 또는 개선용 식품 조성물.A canthopanax koreanum ( Acanthopanax koreanum ) comprising the extract as an active ingredient, a food composition for preventing or improving neuropsychiatric diseases.
  7. (a) 건조한 섬오가피 시료 중량의 1 내지 100배(v/w)의 물, 탄소수 1 내지 6의 알코올 또는 이들의 혼합 용매를 가하여 25℃ 내지 120℃에서 1시간 내지 8시간동안 추출하는 단계; 및(a) adding 1 to 100 times (v / w) of water, alcohol having 1 to 6 carbon atoms or a mixed solvent thereof, and extracting for 1 to 8 hours at 25 ° C to 120 ° C; And
    (b) 상기 (a) 단계에서 추출한 물을 여과, 감압농축 및 건조하는 단계를 포함하는, 제1항 내지 제5항 중 어느 한 항의 조성물의 제조방법.(b) filtration, concentration under reduced pressure and drying the water extracted in the step (a), the method for producing a composition of any one of claims 1 to 5.
  8. 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경재생용 약학적 조성물. Acanthopanax koreanum ( Acanthopanax koreanum ) comprising a extract as an active ingredient, a pharmaceutical composition for neuronal regeneration.
  9. 제8항에 있어서, 상기 조성물은 DCX(Doublecortin)의 발현을 증가시키는 것인 조성물.The composition of claim 8, wherein the composition increases expression of Doublecortin (DCX).
  10. 섬오가피(Acanthopanax koreanum) 추출물을 유효성분으로 포함하는, 신경재생용 식품 조성물. Acanthopanax koreanum extract containing the extract as an active ingredient, a neurological regeneration food composition.
  11. 신경정신 질환 의심 개체에 섬오가피(Acanthopanax koreanum) 추출물을 투여하는 단계를 포함하는, 신경 정신 질환의 치료방법.A method for treating neuropsychiatric disorders comprising administering Acanthopanax koreanum extracts to a suspicious neuropsychiatric subject.
PCT/KR2013/003257 2012-11-30 2013-04-17 Composition comprising acanthopanax koreanum extract as active ingredient for preventing or treating neuropsychiatric disorders WO2014084460A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120138538A KR101502667B1 (en) 2012-11-30 2012-11-30 A composition for preventing or treating neuropsychiatric disorders, comprising extracts of Acanthopanax koreanum
KR10-2012-0138538 2012-11-30

Publications (1)

Publication Number Publication Date
WO2014084460A1 true WO2014084460A1 (en) 2014-06-05

Family

ID=50828065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/003257 WO2014084460A1 (en) 2012-11-30 2013-04-17 Composition comprising acanthopanax koreanum extract as active ingredient for preventing or treating neuropsychiatric disorders

Country Status (2)

Country Link
KR (1) KR101502667B1 (en)
WO (1) WO2014084460A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018174294A1 (en) * 2017-03-24 2018-09-27 株式会社サン・クロレラ Autonomic nerve regulator, food composition for autonomic nerve regulation, and related technology
WO2018181136A1 (en) * 2017-03-31 2018-10-04 株式会社サン・クロレラ Method for producing anxiolytic drug and anxiolytic food product composition, and technology pertaining thereto
CN109464447A (en) * 2018-11-20 2019-03-15 江苏省中国科学院植物研究所 Laricin is preparing the application in anti-depression drug

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109223747A (en) * 2018-11-20 2019-01-18 江苏省中国科学院植物研究所 Acanthoic acid is preparing the application in anti-depression drug

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020015540A (en) * 2000-08-22 2002-02-28 김상근 Food materials for preventing dementia and foods using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020015540A (en) * 2000-08-22 2002-02-28 김상근 Food materials for preventing dementia and foods using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JUNG, J. M. ET AL.: "Anti-stress effects of Acanthopanax korean um and Crataegus pinnatifida in mice", SOCIETY FOR NEUROSCIENCE, NEUROSCIENCE 2012 CONFERENCE, October 2012 (2012-10-01) *
KO, SANG YUN ET AL.: "Effects of Acanthopanax korean um on experimental stress-induced anxiety or depression-like behavior in mice", THE 18TH RESEARCH INSTITUTE OF PHARMACY, KYUNG HEE EAST-WEST SYMPOSIUM, 23 November 2012 (2012-11-23), pages 28 *
LEE, D. ET AL.: "Neuroprotective effects of Eleutherococcus senticosus bark on transient global cerebral ischemia in rats", JOURNAL OF ETHNOPHARMACOLOGY, vol. 139, 27 May 2011 (2011-05-27), pages 6 - 11 *
WENG, S. ET AL.: "Comparison of the addition of Siberian ginseng (Acanthopanax senticosus) versus fluoxetine to lithium for the treatment of bipolar disorder in adolescents: a randomized, double-blind trial", CURRENT THERAPEUTIC RESEARCH, vol. 68, no. 4, 2007, pages 280 - 290 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018174294A1 (en) * 2017-03-24 2018-09-27 株式会社サン・クロレラ Autonomic nerve regulator, food composition for autonomic nerve regulation, and related technology
JPWO2018174294A1 (en) * 2017-03-24 2020-01-23 株式会社サン・クロレラ Autonomic nervous control agent, food composition for autonomic nervous control, and related technology
WO2018181136A1 (en) * 2017-03-31 2018-10-04 株式会社サン・クロレラ Method for producing anxiolytic drug and anxiolytic food product composition, and technology pertaining thereto
CN109464447A (en) * 2018-11-20 2019-03-15 江苏省中国科学院植物研究所 Laricin is preparing the application in anti-depression drug

Also Published As

Publication number Publication date
KR20140070265A (en) 2014-06-10
KR101502667B1 (en) 2015-03-13

Similar Documents

Publication Publication Date Title
WO2010058926A2 (en) Pharmaceutical composition containing ginger extract or shogaol
US20100272837A1 (en) Traditional chinese medicinal compositions for treating depression , formulation thereof, method for preparing the same thereof
WO2014084460A1 (en) Composition comprising acanthopanax koreanum extract as active ingredient for preventing or treating neuropsychiatric disorders
Li et al. The anti-hyperglycemic effect of plants in genus Gynura Cass.
KR101704918B1 (en) Pharmaceutical composition comprising the extracts of mixed crude drugs for the prevention or treatment of the Parkinson's disease
KR101341693B1 (en) Composition comprising the extract of herbs for preventing or treating neurodegenerative disorders
KR101805801B1 (en) Pharmaceutical composition for prevention or treatment of Parkinson's disease comprising tilianin
WO2018030581A1 (en) Composition for relieving hangovers
WO2014171583A1 (en) Composition for preventing or treating stroke or degenerative brain disease
WO2018008973A1 (en) Composition comprising forsythiae fructus extract as effective ingredient for preventing, ameliorating or treating peripheral neuropathy
KR102358713B1 (en) Compositions containing Acanthopanax sessiliflorum, Fagopyri Semen and Chaenomelis Fructus extracts for the Improvement of Allergic Rhinitis and Manufacturing Method Thereof
CN113082085A (en) Cistanche tubulosa extract and preparation method thereof
WO2014038878A2 (en) Composition for brain-neuron protection and brain-disease prevention, alleviation or treatment comprising muskrat musk
KR101167628B1 (en) A composition comprising black ginseng for treating or preventing dementia and improving cognitive function
CN111346102A (en) Application of baicalin in treating and preventing non-alcoholic fatty liver disease
WO2017142255A1 (en) Composition containing medicinal herb extract as active ingredient for preventing, alleviating, or treating stress or depression
KR101186379B1 (en) Pharmaceutical composition for treating ADHD
US20220354917A1 (en) Pharmaceutical composition, pharmaceutical composition for animal, and food composition, each comprising natural substance extract, and preparation method therefor
KR101142838B1 (en) Composition comprising Cyperus rotundus for preventing or treating of neurodegenerative disease and menopausal brain disorder
CN114931214B (en) Chinese herbal medicine composition for improving hearing impairment and preparation method and application thereof
WO2021085741A1 (en) Composition for ameliorating or treating alzheimer's dementia, comprising tetragonia tetragonioides as active ingredient
WO2021020857A1 (en) Use of composition for prevention, alleviation or treatment of bone loss disorders, containing extracts of reynoutria japonica and cassiae cortex interior
KR20220103326A (en) Composition for improvement, prevention or treatment of depression comprising herbal medicine mixture as effective component
KR101914738B1 (en) Composition for Preventing or Improving Dementia Comprising a Dried Flower Bud Powder and Root of Black Panax Ginseng
KR20160008132A (en) Composition for preventing or treating of oxidative brain injury and brain function disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13858053

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 30.09.2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13858053

Country of ref document: EP

Kind code of ref document: A1